Archived AES Symposia 2004
Neuroprotection and Epilepsy
Recent Developments and Future Possibilities
Program Length: 3 hrs 5 min
The symposium will begin with a review of the basic science behind cellular injury resulting from seizures. Next, possible targets and opportunities for interventions with neuroprotective agents will be discussed. The next presentation will summarize clinical models of neuroprotection and describe drugs that have failed to show neuroprotective properties. Finally, a summary of the status of anti-epileptic drugs (AEDs) in the arena of neuroprotection will be presented, focusing on recent accomplishments and possibilities for the future.
At the conclusion of this activity, participants should be able to:
- Understand the mechanisms behind cellular injury from seizures
- Identify the targets and opportunities for intervention with neuroprotective agents
- Discuss clinical models of neuroprotection
- Recognize the current status of AEDs in neuroprotection and understand their possible roles in the future.
Neurologists, epileptologists, clinical and basic researchers, and other allied health professionals with an interest in neuroprotection.
Chair: Raman Sankar, M.D., Ph.D.
- Seizures and Cellular Injury: Understanding the Connection
Denson G. Fujikawa, M.D.
- Interventions With Neuroprotective Agents: Targets and Opportunities
Patrick G. Sullivan, Ph.D.
- Anti-epileptic Drugs and Neuroprotection: Current Status and Future Roles
L. James Willmore, M.D.
This program and its re-purposing on the AES Web site with CME credit is supported by an educational grant from Eisai Inc.
Dr Fujikawa has disclosed that he will not be discussing the unlabeled/unapproved use of any product in his presentation.
Dr Sullivan has disclosed that he will not be discussing the unlabeled/unapproved use of any product in his presentation.
Dr Willmore has indicated that he receives research support from Abbott Laboratories; Athena Neurosciences, Inc; GlaxoSmithKline; Ciba-Geigy Corp; Dainippon Pharmaceutical Co, Ltd; Ortho-McNeil Pharmaceutical, Inc; Hoechst Marion Roussel, Inc; National Institutes of Health; Novartis Pharmaceuticals; Parke-Davis Corp; UCB Pharma Inc; and R.W. Johnson Pharmaceuticals. Dr Willmore is a member of the speaker's bureau for Abbott Laboratories; Elan Pharmaceuticals, Inc; GlaxoSmithKline; Novartis Pharmaceuticals; Ortho-McNeil Pharmaceuticals Inc; Parke-Davis Corp; and Pfizer, Inc. Dr Willmore has indicated that he does not intend to reference unlabeled/unapproved uses of drugs or products in his presentation.